Introduction: Cancer is associated with signiÞ cant psychosocial morbidity and has impact on quality of life. An appropriate psychiatric management of cancer patient may improve the ultimate quality of living.
INTRODUCTION
Many researchers have reported that six mental disorders occur more frequently in cancer patients to warrant a detailed assessment and clinical intervention. Three represent direct reaction to illness: adjustment disorders with depression and/or anxiety, major depression and delirium. Others (primarily anxiety disorders, personality disorders and major depressive disorders) are pre-existing conditions often exacerbated by the illness 1, 2 .
Various studies over the years have shown that treatment outcome of psychiatric morbidities in cancer patients have an excellent outcome. In noncontrolled studies of depressed cancer patients, response rates of 73 to 100% have been attained 3 . In a study of 146 patients with cancer referred to a liaison psychiatry service, antidepressants were prescribed for 67% of patients with 80% showing good clinical response to treatment with few side effects 4. Valente SM (1997) also quote that an approximate 80 -90% of depressed patients are effectively treated with psychotherapy, and/or pharmacological or somatic interventions 5 .
A recent Indian study identiÞ ed 44% cancer patients as probable psychiatric cases on the basis of GHQ 12 (Cutoff >2) and this number had signiÞ cantly reduced to 12 (24%) after psychiatric treatment. On the Carroll Rating Scale for Depression a cut-off of b>10 had identiÞ ed 78% patients as depressed prior to treatment. After psychiatric treatment, this fell to 42% 6 .
This cross sectional study was designed to assess the outcome of treatment of anxiety and depression in cancer patients and its effect in their quality of life.
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METHODS
This cross sectional study was carried out from 24 th Feb 2012 for duration of six weeks, on cancer patients with psychiatric morbidity at Shree Birendra Hospital.The interviewer introduced himself as a doctor conducting a study of psychiatric morbidities in cancer patients. All the subjects in the study were explained the nature and importance of the study and informed consent was obtained from each for the study and as well as for the treatment. The cases include army personnel and their dependants, irrespective of cancer types, either as a freshly diagnosed case or known cases for surgery or follow up cycles of chemotherapy or radiotherapy. Those who were severely or terminally ill or patients undergoing treatment at ICU and patients suffering from other concomitant illnesses were excluded from this study.
Eighteen cancer patients, observed to have possible psychiatric co-morbidity, were enrolled in this study and random sampling was done.
All the eighteen patients were administered the following psychological tests:
A. GHQ (General Health Questionnaire):
GHQ is a screening instrument developed to assess the extent of non-psychotic psychiatric illness and current mental well being for the past few weeks 7 . It is extensively used in both community settings and general practice. This scale has been extensively validated over cultures, languages, age groups (except extremes of ages), gender and education with very high sensitivity and speciÞ city. GHQ 12 was used in present study. Scoring was done by using binary method with 2 as cut off score.
B. Hospital anxiety and depression scale (HADS):
The HADS is a self-report questionnaire developed to detect adverse anxiety and depressive states 8 .
Since it was developed for use in non-psychiatric departments, it does not rely upon symptoms that may be present in people with physical illness alone, such as pain and weight loss. It has 14 items, 7 related to anxiety and 7 to depression. Scoring is from 0-3 and score ranges from 0-56. The norms give an idea of the level of anxiety and depression (0-7=normal, 8-10=mild, 11-14= moderate and 15-21=severe).In the present study, HADS has been used to assess anxiety and depression in cancer patients.
C. WHO QOL BREF Scale:
The WHO QOL BREF assessments are made under four domains : 1) physical health domain, 2) psychological health domain, 3) social relationship domain. 4) environmental domain. The normal physical health domain scores range from 7 -35; for psychological health domain, it ranges from 6 -30. The normal social relationship domain scores range from 3 -15 and for environmental domain, it ranges from 8 -40. Higher scores indicate better quality of life.
Probable psychiatric morbidity was screened by using the General Health Questionare (GHQ) with a cutoff of >2 for cancer patients. Both anxiety and depression was assessed by using the Hospital anxiety and depression scale (HADS) taking a cutoff of >7. Quality of Life (on all 4 domains) was assessed by using the WHO QOL Scale.
Treatment was given for a period of 4 to 6 weeks only to those cancer patients scoring above 7 on the HADS scale for a period of 4 to 6 weeks. They were followed up regularly and a Þ nal follow up was done after 4 to 6 weeks of the initial evaluation where all the cancer patients, who had psychiatric morbidity, were reassessed with structured proforma and all the test materials to Þ nd out the response to treatment.
Frequency data were compared by using the 'chi' square test. For comparing the scores of psychological tests nonparametric tests were used.Wilcoxon test was used for comparing scores (of pretreatment and post treatment group) on psychiatric rating scales. The differences were considered signiÞ cant if the 'p' value was less than 0.05. Statistical analysis was done in computer package.
RESULTS
All eighteen cancer patients had an GHQ score of more than 2 thus having a probable non psychotic psychiatric illness. The mean GHQ scores of cancer patients prior to treatment was 6.67 (SD=3.0293) and post treatment the score reduced to 4.67 (SD =3.124) ( Table 8) . Nine (50%) out of eighteen patients who received treatment improved (Table 1 ). The mean anxiety score was 10 (SD=1.7889) before treatment and 7.81 (SD=2.167) post treatment ( Table 8 ). The distibution of anxiety scores before and after treatment is given in Table 2 . Of the patients who received treatment for anxiety, seven (43.75%) improved as per HADS cutoff of <7.The difference was statistically signiÞ cant (p= <0.05) ( Table 2 ).The mean depression score was 12.33 (SD = 2.38) before treatment and 9.16 (SD=2.44) following treatment. The difference was statistically signiÞ cant (Wilcoxon test; p=0.002; Table  8 ). The distribution of depression scores before and after treatment is shown in Table 8 ). The distribution of environmental domain scores before and after treatment is shown in Table 7 . 
DISCUSSION
In the current study, treatment was given to only eighteen patients; ten had both anxiety and depression, two had only depression and six had only anxiety.
The mean GHQ scores of cancer patients prior to treatment was 6.67 (SD=3.0293) and post treatment the score reduced to 4.67 (SD =3.124). Post treatment 9 (50%) patients scored <2 showing that 50% of patients who received treatment improved as per GHQ cut off below 2 (Table 1) but there was an overall decrease in GHQ scores and it was statistically signiÞ cant (Wilcoxon test; p = 0.001; Table 8 ). GHQ score distribution is shown in Table 1 .
The anxiety score of 18 patients, who received treatment, had a mean score of 10 (SD=1.7889), which reduced to a mean score of 7.81 (SD=2.167)-post treatment (Table 8) . Seven (43.75%) patients improved following treatment, as per HADS cut off of below 7. This was statistically signiÞ cant (p=<0.05; Table 2 ). The anxiety score distribution is shown in Table 2 . All seven patients who improved were of the mild anxiety group; however, there was overall reduction of scores of other patients as well but did not reach 7 or below (Wilcoxon test, p=0.001; Table 2 ).
The depression score of 18 patients, who received treatment, had a mean score of 12.33 (SD = 2.38) which reduced to 9.16 (SD=2.44) following treatment (Table 8) . Five (41.66%) patients showed improvement following treatment as per HADS cutoff of below 7. This was not statistically signiÞ cant (p=0.181; Table 31 ). This may be due to the fact that patients were given short term treatment for a period of 4 to 6 weeks. But there was overall decrease in depression scores following treatment which was statistically signiÞ cant (Wilcoxon test, p=0.002, Table  28 ). Of the Þ ve patients who improved, as per cut-off of <7, 2 were mildly depressed and 3 were moderately depressed. There was reduction in score of the severely depressed patients as well but it did not reach 7 or below after treatment. The depression score distribution is presented in Table 3 .
The WHO QOL (physical domain score) ranged from 9 to 32 with a mean of 18.89 (SD=7) before treatment and following treatment this ranged from 11-34 with a mean of 21.39 (SD= 5.97). There was overall increase in QOL (physical domain score) which was statistically signiÞ cant (Wilcoxon test; Table 8 ). The distribution of WHO QOL (psychological domain score) is presented in Table 5 .
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The WHO QOL (social relationship domain score) ranged from 7 to 13 with a mean of 9. Table 28 ). The distribution of WHO QOL (environmental domain score) is presented in Table 7 .
The response to treatment was 50% as assessed by GHQ following treatment of psychiatric morbidity ( Table 1 ). The response to treatment for depression was (41.66%) ( Table 2 ) and for anxiety was (43.75%) ( Table 3 ) based on cut off of <7 but there was overall decrease in scores ( 9 Olin and Masard (1996) 10 -80%, Natenshon (1956) 11 -96.1%. The discrepancy may be due to the fact that all the patients in this study were treated for a very short time (4-6 weeks). The choice of psychotropic drugs also is considered another factor resulting in variation of response as medicines prescribed varied across other studies and the present study. Natenshon (1956) 11 had treated patients for upto 26 weeks with methyl phenidate which might have resulted in such a high response (96.1%). All 3 studies by Fernandes et al (1987) 9 , Olin and Masand (1996) 10 and Natenshon (1956) 11 had used psycho stimulants whereas none of our patients were treated with psycho stimulants. The other reason for low response rate may be due to the fact that most of our patients were admitted for cycles of radiotherapy and chemotherapy. Studies have shown that there is duplication of depressive symptoms during course of chemotherapy and severe depression is noted to increase from 0 -17% during such period 12 . Radiotherapy also tends to increase risk of depression via fatigue syndrome and this may also have resulted in low response rate as compared to other studies 13, 14 .
There was overall improvement in quality of life in all four domains following treatment, but was statistically signiÞ cant in case of Þ rst two domains (Table 8) . This was consistent with Þ nding as per study conducted by Pathak et al (2000) 15 .
Possible limitation of this study could be small and random sample size. Patients were provided treatment for a limited period of time (4-6 weeks) as against a minimum period of six months which are given to patients with primary depression and anxiety.
CONCLUSIONS
Present study shows that treatment leads to reduction in psychopathology and improvement in quality of life. Oncology centres and institutions working in close liaison with psychiatrists can signiÞ cantly reduce the psychopathology of cancer patients as well as improve their quality of life.
